RO-0282425

RO-0282425
Clinical data
Other namesRO0282425
Routes of
administration		Unspecified[1]
Drug classMelanocortin MC4 receptor agonist
ATC code
  • None

RO-0282425 is a melanocortin MC4 receptor agonist which was under development for the treatment of erectile dysfunction but was never marketed.[1][2] Its route of administration was unspecified.[1] The drug was under development by Roche.[1][2] It reached phase 2 clinical trials by 2005 but its development was subsequently discontinued.[1][2] The chemical structure of RO-0282425, and whether it is a small molecule or a peptide, do not appear to have been disclosed.[1]

See also

References

  1. ^ a b c d e f "RO 0282425". AdisInsight. 4 March 2010. Retrieved 27 January 2026.
  2. ^ a b c "Delving into the Latest Updates on RO-0282425 with Synapse". Synapse. 3 January 2026. Retrieved 27 January 2026.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.